Oxford Biomedica PLC Admission of Shares and Total Voting Rights

RNS Number : 9531S

Oxford Biomedica PLC

19 June 2024

 

 

 

 

Oxford Biomedica

Admission of Shares and Total Voting Rights

 

 

Oxford, UK - 19 June 2024: Oxford Biomedica plc (LSE:OXB) ("Oxford Biomedica" or "the Company"), a quality and innovation-led cell and gene therapy CDMO, today announces that further to the announcement made on 18 June 2024 regarding the subscription of shares by TSGH SAS, a subsidiary of Institut Mérieux SA in respect of a EUR 20 million (£16.9 million) investment, the Company confirms that 5,201,107 new Ordinary Shares of 50 pence each have been admitted today to the Premium segment of the Official List and to trading on the Main Market of the London Stock Exchange and the Company's issued share capital now consists of 105,268,630 ordinary shares of 50 pence each ("Ordinary Shares"). There are no Ordinary Shares held in treasury.

 

Accordingly, the total number of voting rights in Oxford Biomedica plc at the date of this announcement is 105,268,630.

 

The above figure 105,268,630 may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, Oxford Biomedica plc under the FCA's Disclosure Guidance and Transparency Rules.

 

 

 

-Ends-

 

For further information, please contact:
Oxford Biomedica plc: Natalie Walter, Company Secretary	Tel: [phone]

 

ABOUT OXFORD BIOMEDICA

 

Oxford Biomedica (LSE: OXB) is a quality and innovation-led contract development and manufacturing organisation (CDMO) in cell and gene therapy with a mission to enable its clients to deliver life changing therapies to patients around the world.

 

One of the original pioneers in cell and gene therapy, OXB has more than 25 years of experience in viral vectors; the driving force behind the majority of cell and gene therapies. OXB collaborates with some of the world's most innovative pharmaceutical and biotechnology companies, providing viral vector development and manufacturing expertise in lentivirus, adeno-associated virus (AAV), adenovirus, and other viral vector types. Oxford Biomedica's world-class capabilities span from early-stage development to commercialisation. These capabilities are supported by robust quality-assurance systems, analytical methods and depth of regulatory expertise.

 

Oxford Biomedica, a FTSE4Good constituent, is headquartered in Oxford, UK. It has bioprocessing and manufacturing facilities across Oxfordshire, UK, Lyon and Strasbourg, France, and near Boston, MA, US. Learn more at www.oxb.com, and follow us on LinkedIn and YouTube.

 

 

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [e-mail] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

 

END

 

 

TVRSFIFWAELSEDM